Pure Global
NCT06154226

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor: A Prospective Randomized Controlled Trial
The University of Texas Health Science Center, Houston·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Pantoprazole
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The University of Texas Health Science Center, Houston
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Dec 01, 2023
End date
Feb 01, 2025
Enrollment
100 participants
Primary outcome

The area under the curve (AUC) of urinary kidney injury biomarkers KIM-1 above baseline within 24 hours postoperatively

Summary

The purpose of this study is to determine whether perioperative intravenous administration of
 pantoprazole will improve kidney function parameters following cardiac surgery with
 cardiopulmonary bypass compared to famotidine and to determine whether perioperative
 intravenous administration of pantoprazole will decrease the incidence of postoperative Acte
 Kidney Injury (AKI) and major adverse kidney events (MAKE)

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06154226
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06154226 through Pure Global AI's free database. This Phase 4 trial is sponsored by The University of Texas Health Science Center, Houston and is currently Not yet recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.